Use of positron emission tomography in anticancer drug development

被引：21
|
作者：
Aboagye, EO [1 ]
Price, PM [1 ]
机构：
[1] Hammersmith Hosp, Dept Canc Med, Fac Med, Imperial Coll Sci Technol & Med,PET Oncol Grp, London, England
来源：
INVESTIGATIONAL NEW DRUGS | 2003年 / 21卷 / 02期
关键词：
positron emission tomography; pharmacokinetics; pharmacodynamics; modeling; anticancer; drug development;
D O I：
10.1023/A:1023521412787
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[C-11]thymidine, [F-18]fluorodeoxyglucose, (H2O)-O-15, (CO)-O-15, and receptor ligands.
引用
收藏
页码：169 / 181
页数：13
相关论文
共 50 条
  • [21] The application of positron emission tomography (PET) imaging in CNS drug development
    Ivonne Suridjan
    Robert A. Comley
    Eugenii A Rabiner
    [J]. Brain Imaging and Behavior, 2019, 13 : 354 - 365
  • [22] Positron emission tomography imaging as a key enabling technology in drug development
    McCarthy, T. J.
    [J]. PET Chemistry: THE DRIVING FORCE IN MOLECULAR IMAGING, 2007, 62 : 329 - 339
  • [23] Positron emission tomography in central nervous system drug discovery and development
    Cooper, M
    Metz, J
    [J]. NEUROIMAGING CLINICS OF NORTH AMERICA, 2003, 13 (04) : 851 - +
  • [24] Imaging pulmonary inflammation with positron emission tomography: A biomarker for drug development
    Chen, Delphine L.
    Schuster, Daniel P.
    [J]. MOLECULAR PHARMACEUTICS, 2006, 3 (05) : 488 - 495
  • [25] Positron emission tomography (PET): Expanding the horizons of oncology drug development
    Hammond, LA
    Denis, L
    Salman, U
    Jerabek, P
    Thomas, CR
    Kuhn, JG
    [J]. INVESTIGATIONAL NEW DRUGS, 2003, 21 (03) : 309 - 340
  • [26] The application of positron emission tomography (PET) imaging in CNS drug development
    Suridjan, Ivonne
    Comley, Robert A.
    Rabiner, Eugenii A.
    [J]. BRAIN IMAGING AND BEHAVIOR, 2019, 13 (02) : 354 - 365
  • [27] Positron emission tomography (PET): Expanding the horizons of oncology drug development
    Lisa A. Hammond
    Louis Denis
    Umber Salman
    Paul Jerabek
    Charles R. Thomas
    John G. Kuhn
    [J]. Investigational New Drugs, 2003, 21 : 309 - 340
  • [28] Trends in use of positron emission tomography
    Tashiro, M
    Kubota, K
    Itoh, M
    Moser, E
    [J]. LANCET, 2001, 357 (9259): : 886 - 886
  • [29] Use of positron emission tomography in sarcoidosis
    Bonardel, G.
    Carmoi, T.
    Gontier, E.
    Lecoules, S.
    Cambon, A.
    Foehrenbach, H.
    Algayres, J. -P.
    [J]. REVUE DE MEDECINE INTERNE, 2011, 32 (02): : 101 - 108
  • [30] The use of positron emission tomography in hepatology
    Shiomi, S
    [J]. HEPATOLOGY RESEARCH, 2005, 31 (02) : 63 - 68
12345